Effective Fraction of Inspired Oxygen With Nasal Cannula in Premature Infants

University of Miami logo

University of Miami

Status

Completed

Conditions

Oxygen Therapy

Treatments

Other: Nasal cannula flow rate

Study type

Observational

Funder types

Other

Identifiers

NCT03431818
20170816

Details and patient eligibility

About

The objective of this study is to determine the multifactorial relationship between the effective fraction of inspired oxygen (Effective-FiO2) and the FiO2 in the gas delivered by the nasal cannula (NC-FiO2), NC flow rate, spontaneous minute ventilation and other patient characteristics in premature infants who receive supplemental oxygen via nasal cannula (NC).

Full description

During routine nasal cannula (NC) use in the newborn ICU, the actual fraction of oxygen inspired by the infant, i.e. the effective FiO2 (Effective-FiO2) that reaches the infant's airways, cannot be easily determined. The effective FiO2 during NC use is generally lower than the FiO2 in the gas delivered by NC at the infant's nose due to dilution with ambient gas entrained by the infants during spontaneous inspiration. The factors influencing effective FiO2 include the set FiO2 of the gas delivered by NC (NC-FiO2), the NC-flow rate, and the entrainment of ambient gas by the infant during each spontaneous inspiration. The individual contribution of each of these factors to the variability in effective-FiO2 in extreme premature infants has not been systematically evaluated. The objective of this study is to determine the multifactorial relationship between the effective fraction of inspired oxygen (Effective-FiO2) and the FiO2 in the gas delivered by the nasal cannula (NC-FiO2), NC flow rate, spontaneous minute ventilation and other patient characteristics in premature infants who receive supplemental oxygen via nasal cannula (NC).

Enrollment

35 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Premature infants born between 23 and 30 weeks of gestational age
  • Receiving supplemental oxygen via nasal cannula
  • Parental informed consent

Exclusion criteria

  • Major congenital anomalies
  • Clinically unstable

Trial contacts and locations

1

Loading...

Central trial contact

Carmen D'Ugard; Ana C Aguilar

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems